At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.
Multigene testing appears to be feasible in Asian breast cancer patients, resulting in a higher diagnostic yield and detecting pathogenic genetic mutations beyond the usual BRCA1/2 genes, according to a new Singapore study.
Elderly, vulnerable patients with metastatic colorectal cancer (CRC) experienced longer progression-free survival (PFS) and fewer toxicities with a reduced-dose combination chemotherapy regimen of S-1 and oxaliplatin compared with full-dose S-1 monotherapy, the phase II NORDIC9* trial showed.
New drug applications approved by US FDA as of 01 - 15 March 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Statins appear to lower the risk of postcolonoscopy colorectal cancer (PCCRC), which is defined as CRC occuring before the expected interval following an initial negative colonoscopy, as shown in a recent study from Hong Kong. Specifically, this protective effect is greater in older patients, women, and those without diabetes mellitus or polyps.
Patients with renal cell carcinoma (RCC) who received the first-line combination of avelumab and axitinib had longer progression-free survival (PFS) compared with those who received sunitinib, particularly those with PD-L1–positive tumours, according to findings of the phase III JAVELIN Renal 101* trial.
The addition of a 4-week chemotherapy regimen comprising 5-fluorouracil (5FU) and leucovorin administered during the resting period between preoperative chemoradiotherapy (CRT) and surgery improves tumour downstaging and survival rates in individuals with locally advanced rectal cancer (LARC), according to a new study.
Patients with extensive stage small cell lung cancer (ES-SCLC) without brain metastasis who underwent prophylactic cranial irradiation (PCI) after achieving stable disease or better on first-line chemotherapy had improved overall survival (OS) compared with those who did not undergo PCI, according to a retrospective study from Singapore.
Roche recently announced their targeted therapy combination pertuzumab (Perjeta®)-trastuzumab (Herceptin®) plus conventional chemotherapy for treatment of early breast cancer in those with a subtype known as HER2-positive. The combination was previously used in the metastatic breast cancer setting, where cancer had already spread. There, it was able to prolong cancer sufferers’ lives significantly. Because of its effectiveness, the two-drug combo is new available for treatment of early HER2-positive breast cancer to further reduce the risk of metastasis or cancer recurrence. HER2-positive breast cancers usually spread faster and affect younger women and make up about one quarter of all newly diagnosed breast cancers.